Animal models of complement-mediated hypersensitivity reactions to liposomes and other lipid-based nanoparticles

Journal of Liposome Research

Volumn 17, Issue 2, 2007, Pages 107-117

  Szebeni, János ^a,b,c   Alving, Carl R ^b   Rosivall, László ^c   Bünger, Rolf ^d   Baranyi, Lajos ^e   Bedöcs, Péter ^f   Tóth, Miklós ^f   Barenholz, Yezheckel ^g  

^a HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^e Vaccine and Immunology Research Institute   (United States)

^f National Institute of Cardiology Budapest   (Hungary)

^g HEBREW UNIVERSITY   (Israel)

Author keywords

Adverse drug reactions; Animal models; Complement; Hypersensitivity; Liposomes; Nanomedicines

Indexed keywords

ALPHA TOCOPHEROL; ANAPHYLATOXIN; ANESTHETIC AGENT; CHOLESTEROL; COMPLEMENT COMPONENT C5A; CREMOPHOR; DIAGNOSTIC AGENT; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DIMYRISTOYLPHOSPHATIDYLGLYCEROL; DOCETAXEL; DOXORUBICIN; HEMOGLOBIN; HYPNOTIC AGENT; LIPOSOME; NANOPARTICLE; PACLITAXEL; PHOSPHOLIPID; POLYSORBATE 80; THROMBOXANE B2;

ANAPHYLACTIC SHOCK; ANIMAL MODEL; BASOPHIL; BLOOD; BLOOD CELL; BODY WEIGHT; CARDIOTOXICITY; COMPLEMENT ACTIVATION; DOG; DOSE RESPONSE; DRUG ERUPTION; DRUG HYPERSENSITIVITY; ECG ABNORMALITY; EXPERIMENTAL MODEL; FLUSHING; HEART ARRHYTHMIA; HEART OUTPUT; HEMODYNAMICS; HUMAN; HYPERSENSITIVITY REACTION; HYPERTENSION; HYPOTENSION; INFLAMMATORY CELL; LEUKOCYTOSIS; LEUKOPENIA; MAST CELL; MEAN ARTERIAL PRESSURE; MICELLE; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT; REPRODUCIBILITY; RESPIRATORY SYSTEM; REVIEW; SKIN MANIFESTATION; SPECIES COMPARISON; SWINE; SYMPTOM; TACHYCARDIA; TACHYPHYLAXIS; THROMBOCYTOPENIA;

ANAPHYLATOXINS; ANIMALS; COMPLEMENT ACTIVATION; DISEASE MODELS, ANIMAL; DOGS; DRUG HYPERSENSITIVITY; HUMANS; LIPIDS; LIPOSOMES; NANOPARTICLES; RATS; SPECIES SPECIFICITY; SWINE;

EID: 34347378637     PISSN: 08982104     EISSN: 15322394     Source Type: Journal    
DOI: 10.1080/08982100701375118     Document Type: Review

References (37)

1. Bala, S., Weaver, J., Hastings, K. L. (2005). Clinical relevance of preclinical testing for allergic side effects. Toxicology 209:195-200.
2. Baranyi, L., Szebeni, J., Sávay, S., Bodo, M., Basta, M., Bentley, T. M., Bunger, R., Alving, C. R. (2003). Complement-dependent shock and tissue damage induced by intravenous injection of cholesterol-enriched liposomes in rats. J. Appl. Res. Clin. Exp. Ther. 3:3. http://jrnlappliedresearch.com/ articles/Vol3Iss3/index.htm
3. Bertram, T. A., Overby, L. H., Danilowicz, R., Eling, T. E., Brody, A. R. (1988). Pulmonary intravascular macrophages produce prostaglandins and leukotrienes in vitro. Chest 93: 82S-84S.
4. Chanan-Khan, A., Szebeni, J., Savay, S., Liebes, L., Rafique, N. M., Alving, C. R., Muggia, F. M. (2003). Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann. Oncol. 14:1430-1437.
5. Chitko-McKown, C. G., Chapes, S. K., Brown, R. E., Phillips, R. M., McKown, R. D., Blecha, F. (1991). Porcine alveolar and pulmonary intravascular macrophages: comparison of immune functions. J. Leukoc. Biol. 50:364-372.
6. de Marie, S. (1996). Liposomal and lipid-based formulations of amphotericin B. Leukemia 10(Suppl. 2):S93-S96.
7. Gabizon, A., Isacson, R., Libson, E., Kaufman, B., Uziely, B., Catane, R., Ben-Dor, C. G., Rabello, E., Cass, Y., Peretz, T., et al., (1994). Clinical studies of liposome-encapsulated doxorubicin. Acta Oncol. 33:779-786.
8. Gabizon, A. A., Muggia, F. M. 1998. Initial clinical evaluation of pegylated liposomal doxorubicin in solid tumors. In Long-Circulating Liposomes: Old Drugs, New Therapeutics. M. C. Woodle, and S. G. Landes Bioscience, Austin, TX, pp. 155-174.
9. Gaca, J. G., Palestrant, D., Lukes, D. J., Olausson, M., Parker, W., Davis, R. D. J. (2003). Prevention of acute lung injury in swine: depletion of pulmonary intravascular macrophages using liposomal clodronate. J. Surg. Res. 112:19-25.
10. Gordon, A. N., Granai, C. O., Rose, P. G., Hainsworth, J., Lopez, A., Weissman, C., Rosales, R., Sharpington, T. (2000). Phase II study of liposomal doxorubicin in platinum- and paclitaxelrefractory epithelial ovarian cancer. J. Clin. Oncol. 18:3093-3100.
11. Henricsson, A., Bergentz, S. E. (1978). Role of platelets and lymphocytes for the hemodynamic effects of rapidly injected antilymphocyte globulin. Eur. Surg. Res. 10:40-49.
12. Hubert, A., Lyass, O., Pode, D., Gabizon, A. (2000). Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer. Anticancer Drugs 11:123-127.
13. Johansson, S. G. O., Bieber, T., Dahl, R., Friedmann, P. S., Lanier, B. Q., Lockey, R. F., Motala, C., Ortega Martell, J. A., Platts-Mills, T., Ring, J., Thien, F. P. V. C., Williams, H. C. (2004). Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J. Allergy Clin. Immunol. 113:832-836.
14. Koukourakis, M. I., Koukouraki, S., Giatromanolaki, A., Archimandritis, S. C., Skarlatos, J., Beroukas, K., Bizakis, J. G., Retalis, G., Karkavitsas, N., Helidonis, E. (1999). Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer. J. Clin. Oncol. 17:3512-3521.
15. Lorenz, W., Riemann, H. J., Schmal, A. (1977). Histamine release in dogs by Cremophor EL and its derivatives: oxyethylated oleic acid is the most effective constituent. Agents Actions 7:63-67.
16. Lyass, O., Uziely, B., Ben-Yosef, R., Tzemach, D., Heshing, N. I., Lotem, M., Brufman, G., Gabizon, A. A. (2000). Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 89:1037-1047.
17. Muggia, F. M., Hainsworth, J. D., Jeffers, S., Miller, P., Groshen, S., Tan, M., Roman, L., Uziely, B., Muderspach, L., Garcia, A., Burnett, A., Greco, F. A., Morrow, C. P., Paradiso, L. J., Liang, L. J. (1997). Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J. Clin. Oncol. 15:987-993.
18. Nierkens, S., Pieters, R. (2005). Murine models of drug hypersensitivity. Curr. Opin. Allergy Clin. Immunol. 5:331-335.
19. Northfelt, D. W., Dezube, B. J., Thommes, J. A., Levine, R., Von Roenn, J. H., Dosik, G. M., Rios, A., Krown, S. E., Du Mond, C., Mamelok, R. D. (1997). Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. J. Clin. Oncol. 15(2):653-659.
20. Ostensen, J., Hede, R., Myreng, Y., Ege, T., Holtz, E. (1992). Intravenous injection of Albunex microspheres causes thromboxane mediated pulmonary hypertension in pigs, but not in monkeys or rabbits. Acta Physiol. Scand. 144:307-315.
21. Poirier, V. J., Hershey, A. E., Burgess, K. E., Phillips, B., Turek, M. M., Forrest, L. J., Beaver, L., Vail, D. M. (2004). Efficacy and toxicity of paclitaxel (Taxol) for the treatment of canine malignant tumors. J. Vet. Intern. Med. 18:219-222.
22. Rabinovici, R., Rudolph, A. S., Feuerstein, G. (1989). Characterization of hemodynamic, hematologic and biochemical responses to administration of liposome-encapsulated hemoglobin in the conscious, freely moving rat. Circ. Shock 29:115-132.
23. Rabinovici, R., Rudolph, A. S., Ligler, F. S., Smith III, E. F., Feuerstein, G. (1992). Biological responses to exchange transfusion with liposome-encapsulated hemoglobin. Circ. Shock 37:124-133.
24. Rabinovici, R., Rudolph, A. S., Yue, T.-L., Feuerstein, G. (1990). Biological responses to liposomeencapsulated hemoglobin (LEH) are improved by a PAF antagonist. Circ. Shock 31:431-445.
25. Szebeni, J. (2001). Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs and radiocontrast agents. Crit. Rev. Ther. Drug Carr. Syst. 18:567-606.
26. Szebeni, J. (2004). Complement activation-related pseudoallergy: Mechanism of anaphylactoid reactions to drug carriers and radiocontrast agents. In The Complement System: Novel Roles in Health and Disease. J. Szebeni. Kluwer, Boston, pp. 399-440.
27. Szebeni, J. (2005). Complement activation-related pseudoallergy: a new class of drug-induced immune toxicity. Toxicology 216:106-121.
28. Szebeni, J., Alving, C. R., Savay, S., Barenholz, Y., Priev, A., Danino, D., Talmon, Y. (2001). Formation of complement-activating particles in aqueous solutions of Taxol: Possible role in hypersensitivity reactions. Intern. Immunopharm. 1:721-735.
29. Szebeni, J., Baranyi, B., Savay, S., Bodo, M., Morse, D. S., Basta, M., Stahl, G. L., Bunger, R., Alving, C. R. (2000). Liposome-induced pulmonary hypertension: Properties and mechanism of a complement-mediated pseudoallergic reaction. Am. J. Physiol. 279:H1319-H1328.
30. Szebeni, J., Baranyi, B., Savay, S., Lutz, L. U., Jelezarova, E., Bunger, R., Alving, C. R. (2000). The role of complement activation in hypersensitivity to pegylated liposomal doxorubicin (Doxil®). J. Liposome Res. 10:347-361.
31. Szebeni, J., Baranyi, L., Savay, S., Bodó, M., Milosevits, J., Alving, C. R., Bünger, R. (2006). Complement activation-related cardiac anaphylaxis in pigs: role of C5a anaphylatoxin and adenosine in liposome-induced abnormalities in ECG and heart Function. Am. J. Physiol. 290:H1050-H1058.
32. Szebeni, J., Baranyi, L., Savay, S., Milosevits, J., Bodo, M., Bunger, R., Alving, C. R. (2003). The Interaction of Liposomes with the Complement System: In Vitro and In Vivo Assays. Methods Enzymol. 373:136-354.
33. Szebeni, J., Fontana, J. L., Wassef, N. M., Mongan, P. D., Morse, D. S., Dobbins, D. E., Stahl, G. L., Bünger, R., Alving, C. R. (1999). Hemodynamic changes induced by liposomes and liposomeencapsulated hemoglobin in pigs: a model for pseudo-allergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody. Circulation 99:2302-2309.
34. Szebeni, J., Muggia, F. M., Alving, C. R. (1998). Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J. Natl. Cancer Inst. 90:300-306.
35. Szebeni, J., Wassef, N. M., Spielberg, H., Rudolph, A. S., Alving, C. R. (1994). Complement activation in rats by liposomes and liposome-encapsulated hemoglobin: evidence for anti-lipid antibodies and alternative pathway activation. Biochem. Biophys. Res. Comm. 205:255-263.
36. Uetrecht, J. (2006). Role of animal models in the study of drug-induced hypersensitivity reactions. AAPS J 7:E 914-921.
37. Uziely, B., Jeffers, S., Isacson, R., Kutsch, K., Wei-Tsao, D., Yehoshua, Z., Libson, E., Muggia, F. M., Gabizon, A. (1995). Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J. Clin. Oncol. 13:1777-1785.